The Latest Cardiac and Vascular News
IRVINE, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) — JenaValve Technology, Inc., developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced that it has appointed Shlomi Nachman, experienced cardiovascular industry executive, to its Board of Directors. Mr. Nachman has over 25 years of experience in the medical device […]
IRVINE, Calif., May 18, 2023 (GLOBE NEWSWIRE) — JenaValve Technology, Inc., developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced the completion of the first two Trilogy Heart Valve System implantations in Asia. The two procedures were performed by Dr. Michael Lee and team at Queen […]
IRVINE, Calif., April 05, 2023 (GLOBE NEWSWIRE) — JenaValve Technology, Inc., developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced that it has appointed Ken MacLeod, Ph.D., life sciences and medical device industry veteran, to its Board of Directors. Dr. MacLeod has over 35 years of […]
IRVINE, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) — JenaValve Technology, Inc., developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced that it has appointed Dan Dearen, medical device industry executive, to its Board of Directors. Mr. Dearen has over 35 years of experience in the medical […]
IRVINE, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) — JenaValve Technology, Inc., developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced that Duane Pinto, MD, MPH, has been appointed as Chief Medical Officer. A leader in interventional cardiology, Dr. Pinto joins JenaValve following more than 20 years […]
Landmark ALIGN-AR Pivotal IDE Study Intended to Evaluate Use of the Trilogy™ Heart Valve System in Treatment of High Surgical Risk Patients with Symptomatic, Severe Aortic Regurgitation IRVINE, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) — JenaValve Technology, Inc., developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today […]
Financing Secures Funding to Complete ALIGN-AR Clinical Trial, Continue E.U. Real World Evidence Development, and Prepare for a U.S. Commercial Launch IRVINE, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) — JenaValve Technology, Inc. (“JenaValve or the “Company”), developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced that […]
IRVINE, Calif., June 28, 2022 (GLOBE NEWSWIRE) — JenaValve Technology, Inc. (“JenaValve” or the “Company”), developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, announced positive results from the first Trilogy Heart Valve System commercial implants for high-surgical risk patients with severe, symptomatic aortic stenosis (AS) or aortic […]
IRVINE, Calif., May 17, 2022 (GLOBE NEWSWIRE) — JenaValve Technology, Inc. (“JenaValve or the “Company”), developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced the appointment of Kari Moore as the Company’s CFO effective May 10th, 2022. “We are excited to welcome Kari to the JenaValve […]
SUZHOU, China, Jan. 19, 2022 /PRNewswire/ — Peijia Medical Limited (HKEX: 9996) is pleased to announce its strategic investment and exclusive in-licensing agreement with JenaValve Technology, Inc. Under the terms of the agreement, Peijia has made a cash and equity investment in JenaValve and will commit additional capital based upon development milestones in […]
